Society Bulletins
Oncol Res Treat 2022;45:466 –470 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 4, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:460 –465 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 4, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:458 –459 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 4, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:456 –457 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 4, 2022 Category: Cancer & Oncology Source Type: research
Durvalumab auch bei Hirnmetastasen vorteilhaft
Oncol Res Treat 2022;45:452 –455 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 4, 2022 Category: Cancer & Oncology Source Type: research
ALL - Blinatumomab verbesserte die Prognose f ür Kinder
Oncol Res Treat 2022;45:450 –451 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 4, 2022 Category: Cancer & Oncology Source Type: research
Nivolumab plus Ipilimumab beim metastasierten Melanom
Oncol Res Treat 2022;45:448 –449 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 4, 2022 Category: Cancer & Oncology Source Type: research
Atezolizumab beim operablen NSCLC
Oncol Res Treat 2022;45:446 –447 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 4, 2022 Category: Cancer & Oncology Source Type: research
Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients: a mono-institutional retrospective analysis.
Conclusions
The outcomes of this series suggest to investigate the possible impact of adding adjuvant CRT to CT in PC patients. Timing, combination of modern CRT with new systemic therapies need to be further investigated to personalize therapy and optimize clinical advantages. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 26, 2022 Category: Cancer & Oncology Source Type: research
Efficacy and safety of bevacizumab in pretreated metastatic breast cancer: a systematic review and meta-analysis
Conclusions: Bevacizumab-containing chemothe rapy, in light of its favorable effects on clinical outcomes, could be a preferred therapeutic option for patients with MBC, for whom the disease must be rapidly relieved. Further studies are warranted for exploring the advantageous patients with the receipt of bevacizumab in multiline treatment. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 26, 2022 Category: Cancer & Oncology Source Type: research
Durable responses to chemotherapy in patients with metastatic soft tissue sarcoma
Conclusion: These observations highlight the potential benefit of chemotherapy in a disease that is often considered to be poorly responsive to this treatment. These observations support further efforts to identify factors to guide patient selection and treatment optimization. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 26, 2022 Category: Cancer & Oncology Source Type: research
Klinische Studien in der H ämatologie und Onkologie
Oncol Res Treat 2022;45(suppl 1):6 –32 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 22, 2022 Category: Cancer & Oncology Source Type: research
Vorwort des DGHO-Vorstandes
Oncol Res Treat 2022;45(suppl 1):5 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 22, 2022 Category: Cancer & Oncology Source Type: research
Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study
Conclusion: The NIS KORALLE provided broad real-world evidence on effectiveness and safety of bevacizumab. Despite different treatment intentions, the combination of bevacizumab plus fluoropyrimidine-based chemotherapy was similarly effective in all subgroups in routine clinical practice. The safety information reported in this study is consistent with the known safety profile of bevacizumab.
ClinicalTrials.gov identifier: NCT01775644 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 20, 2022 Category: Cancer & Oncology Source Type: research
Oncologic rehabilitation in the COVID-19 pandemic: the situation in clinics
Conclusion: Despite a considerable decrease in occupancy in the oncological rehabilitation clinics, the therapies could be changed and carried out in a hygiene-compliant manner. Screening tests were offered at an early stage for patients as well as somewhat delayed for staff. The data show that pandemic-consistently changes in oncological rehabilitation are possible and that supply chains can be maintained. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 18, 2022 Category: Cancer & Oncology Source Type: research
